MedPage Today 
(6/12, Gever) reports, "Patients with treatment-resistant lupus showed
dramatic improvement when they received the myeloma drug bortezomib
(Velcade), a researcher said" at the European League Against
Rheumatism's annual meeting. Between one and "four courses of
bortezomib treatment of 13 patients with refractory systemic lupus
erythematosus (SLE) led to marked reductions in symptom scores and
anti-dsDNA antibodies, according to Reinhard Voll, MD, of University
Medical Center Freiburg in Freiburg, Germany." While "this use
of bortezomib is not currently approved, Voll said it could be an option
in patients who fail to improve with standard immunosuppressant-based
treatment."
No comments:
Post a Comment